KLOW
Copper-Peptide Matrix, Regenerative & Anti-Inflammatory Stack
KLOW — GHK-Cu + BPC-157 + TB-500 + KPV Four-Peptide Blend
Last reviewed: September 2026
KLOW is a Purgo Labs blend of four research peptides in one vial: GHK-Cu (a copper peptide used in skin research), BPC-157 and TB-500 (two animal-studied healing peptides), and KPV (a small anti-inflammatory peptide). It is the Glow Complex with KPV added.
Each part targets a different step of tissue repair: GHK-Cu rebuilds the collagen matrix, BPC-157 grows blood supply, TB-500 moves repair cells into place, and KPV turns down inflammatory signals.
For researchers studying skin, wound or connective-tissue models, a single vial covering four pathways is convenient — provided the fixed ratio suits the experiment.
No study has tested these four together. GHK-Cu has good evidence in skin biology; the other three are animal-study peptides. KLOW is not a hormonal or weight-loss product. Research-only.
What is KLOW?
KLOW is Purgo Labs' four-peptide research blend: 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500 and 10mg KPV co-lyophilized in a single 80mg vial. It is the Glow Complex (GHK-Cu + BPC-157 + TB-500) with the anti-inflammatory tripeptide KPV added — the "K" in the name. The rationale is a skin- and tissue-repair stack: copper-peptide matrix remodelling from GHK-Cu, angiogenic and cytoprotective signalling from BPC-157, actin-regulated cell migration from TB-500, and NF-κB-mediated cytokine suppression from KPV.
Each component has its own literature — GHK-Cu the deepest, BPC-157 and thymosin-β4 substantial in animals, KPV in mouse colitis — but no study has tested the four together. Everything said about KLOW as a blend is inference from the parts. (Correction, 10 September 2026: an earlier version of this page described KLOW as kisspeptin-10, which is a different Purgo product; see the Kisspeptin page.)
- KLOW = GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg, co-lyophilized in one 80mg vial ($124.99 at Purgo Labs, read 10 Sep 2026).
- It is the Glow Complex (GHK-Cu + BPC-157 + TB-500) plus the anti-inflammatory tripeptide KPV.
- Each component has its own literature — GHK-Cu strongest in skin and matrix biology; BPC-157, TB-500 and KPV preclinical — but no study has tested the combination.
- The 5:1:1:1 ratio is supplier-defined; dosing any single component to a literature target fixes the others.
- KLOW is not kisspeptin and has no hormonal or weight-loss evidence; an earlier version of this page conflated the two and was corrected on 10 September 2026.
Molecular Composition
Per 3 mL vial: GHK-Cu 50mg (glycyl-histidyl-lysine copper(II) complex, 403.9 Da), BPC-157 10mg (15-residue gastric pentadecapeptide, 1,419.5 Da), TB-500 10mg (synthetic thymosin-β4 actin-binding fragment, ~889 Da) and KPV 10mg (Lys-Pro-Val, 342.4 Da); 80mg total, lyophilized as one formula. GHK-Cu dominates the mass at 62.5%. Purgo screens the blend as a full formula for purity and identity with a third-party certificate; researchers who need per-component quantitation should request the certificate before use.
How Does It Work?
KLOW stacks four repair-pathway peptides — GHK-Cu for matrix rebuilding, BPC-157 for blood supply, TB-500 for cell migration and KPV for inflammation control — in one 80mg vial; each is studied alone, none together.
The four peptides act through non-overlapping pathways. GHK-Cu delivers copper to the extracellular matrix and modulates several thousand genes, up-regulating collagen, elastin, decorin and antioxidant enzymes while down-regulating inflammatory signalling. BPC-157 promotes angiogenesis via VEGFR2 and nitric-oxide pathways and stabilises the epithelial barrier and gut–brain axis in animal models. TB-500 sequesters G-actin and drives keratinocyte, endothelial and fibroblast migration into wounds, lowering inflammation and scarring. KPV enters cells through the PepT1 transporter and inhibits NF-κB, suppressing TNF-α, IL-6 and IL-1β.
The blend hypothesis is additive rather than synergistic: matrix rebuilding (GHK-Cu), blood supply (BPC-157), cell migration (TB-500) and inflammation control (KPV) address different phases of tissue repair. Pharmacokinetic interaction between the peptides has not been studied, and the doses fixed by the blend ratio (5:1:1:1) may not match the ratios used in any single-agent study.
Key Research Pathways
Copper-Peptide Matrix Remodelling (GHK-Cu)
Copper delivery and gene-expression shifts increase collagen, elastin and decorin synthesis and antioxidant enzyme activity.
Angiogenesis & Cytoprotection (BPC-157)
VEGFR2 and NO-pathway activation improve vascular supply to injured tissue in animal models.
Actin-Regulated Cell Migration (TB-500)
G-actin sequestration accelerates keratinocyte, endothelial and fibroblast migration into wound sites.
NF-κB Suppression (KPV)
PepT1-mediated uptake and NF-κB inhibition lower TNF-α, IL-6 and IL-1β at the site of inflammation.
Key Findings from the Literature
- GHK-Cu modulates expression of thousands of human genes, tilting toward tissue regeneration, collagen synthesis and antioxidant defence (Pickart & Margolina, Int J Mol Sci 2018; PMID 29986520)
- BPC-157 accelerates healing of skin, muscle, tendon, ligament and gastrointestinal lesions across rodent models with a consistent angiogenic and cytoprotective profile (Sikiric et al., Curr Pharm Des 2011)
- Thymosin-β4, the parent of TB-500, promotes dermal and corneal wound repair by driving cell migration and reducing inflammation (Goldstein, Hannappel & Kleinman, Trends Mol Med 2005; PMID 16099219)
- KPV reduced DSS and TNBS colitis in mice after PepT1-mediated uptake into epithelial and immune cells (Dalmasso et al., Gastroenterology 2008; PMID 18061177)
- No published study has evaluated the four-peptide combination; blend claims are extrapolated from single-agent data
Evidence by Claimed Outcome
Each outcome rated by the highest level of evidence available. Tiers follow our 5-tier methodology.
Study counts reflect peer-reviewed publications in the evidence database below. "Theoretical" outcomes have mechanistic rationale only. Learn about our evidence tiers →
Important Research Context
Research References
Peer-reviewed literature supporting the research profile of KLOW
The following peer-reviewed studies form the primary evidence base for KLOW's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018.PMID: 29986520
GHK-Cu resets gene expression toward regeneration: collagen, elastin and antioxidant genes up, inflammatory and fibrotic genes down.
- 2.
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011.PMID: 21548867
Review of BPC-157's cytoprotective, angiogenic and healing effects across rodent injury models.
- 3.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.PMID: 16099219
Thymosin-β4 promotes dermal and corneal wound healing via cell migration and anti-inflammatory effects.
- 4.
Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.PMID: 18061177
KPV reduced colitis in mice after transporter-mediated uptake into epithelial and immune cells.
KLOW
Blends Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
Use code HEALTH for 20% off
Fast FedEx shipping · Discreet packaging
Technical Specifications
| Blend Contents | GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg · KPV 10mg |
| Total Content | 80mg per 3 mL vial |
| Component Ratio | 5 : 1 : 1 : 1 by mass |
| Primary Research Focus | Dermal, matrix and tissue-repair models |
| Form | Lyophilized powder (co-lyophilized) |
| Purity | ≥99% as full formula (third-party COA) |
| Combination Studies | None published |
View full legal status guide →
Source KLOW at Purgo Labs
≥99% purity · Third-party COA · Use code HEALTH for 20% off
Other Compounds in This Guide
Related Research Guides
Supporting Research
Each KLOW component has independent evidence — GHK-Cu in human skin and gene-expression studies; BPC-157, TB-500 and KPV in animal and cell models. No study has evaluated the four-peptide blend.
References
- Pickart L, Margolina A.HUMAN — topical skin studies / gene dataInternational Journal of Molecular Sciences. 2018. PubMedGHK-Cu component: regenerative gene-expression profile and skin-study evidence.
- Dalmasso G, et al.PRECLINICAL — mouseGastroenterology. 2008. PubMedKPV component: anti-inflammatory effect in colitis models.
Research Databases
Ready to Source KLOW?
Purgo Labs offers KLOW with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.